QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

NCT ID: NCT02384954

Last Updated: 2024-07-03

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-17
• Study Completion Date: 2020-12-13

Brief Summary

This is a Phase I/II, open-label, multi-center, competitive enrollment and dose escalation study of N-803 in patients with relapse/refractory indolent B cell non-Hodgkin lymphoma in conjunction with rituximab.

Detailed Description

The purpose of this study is to evaluate the safety and tolerability, identify the Maximum Tolerated Dose (MTD) or the Minimum Efficacious Dose (MED) and designate a dose level for Phase 2. Also characterize the immunogenicity, pharmacokinetic profile, and biomarker serum levels of N-803 in treated patients.

The effect of N-803 on the peripheral absolute lymphocyte counts and white blood cell counts, the number, phenotype and repertoire of peripheral blood T (total and subsets) and NK cells will be evaluated. In addition, a subset of patients will be evaluated for changes in lymph node immune composition. Anti-tumor responses and survival data will also be collected in this trial.

Conditions

Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Phase 1 Cohort 1: N-803 - IV 1 ug/kg

Group Type: EXPERIMENTAL

Rituximab

Intervention Type: BIOLOGICAL

Intravenous infusion 375 mg/m\^2.

N-803

Intervention Type: BIOLOGICAL

Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

Phase 1 Cohort 2: N-803 - IV 3 ug/kg

Group Type: EXPERIMENTAL

Rituximab

Intervention Type: BIOLOGICAL

Intravenous infusion 375 mg/m\^2.

N-803

Intervention Type: BIOLOGICAL

Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

Phase 1 Cohort 3: N-803 - IV 6 ug/kg

Group Type: EXPERIMENTAL

Rituximab

Intervention Type: BIOLOGICAL

Intravenous infusion 375 mg/m\^2.

N-803

Intervention Type: BIOLOGICAL

Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

Phase 1 Cohort 4: N-803 - SQ 6 ug/kg

Group Type: EXPERIMENTAL

Rituximab

Intervention Type: BIOLOGICAL

Intravenous infusion 375 mg/m\^2.

N-803

Intervention Type: BIOLOGICAL

Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

Phase 1 Cohort 5: N-803 - SQ 10 ug/kg

Group Type: EXPERIMENTAL

Rituximab

Intervention Type: BIOLOGICAL

Intravenous infusion 375 mg/m\^2.

N-803

Intervention Type: BIOLOGICAL

Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

Phase 1 Cohort 6: N-803 - SQ 15 ug/kg

Group Type: EXPERIMENTAL

Rituximab

Intervention Type: BIOLOGICAL

Intravenous infusion 375 mg/m\^2.

N-803

Intervention Type: BIOLOGICAL

Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

Phase 1 Cohort 7: N-803 - SQ 20 ug/kg

Group Type: EXPERIMENTAL

Rituximab

Intervention Type: BIOLOGICAL

Intravenous infusion 375 mg/m\^2.

N-803

Intervention Type: BIOLOGICAL

Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

Phase 2 Cohort 1: Anti-CD20 mAb-sensitive N-803 - SQ 20 ug/kg

Group Type: EXPERIMENTAL

Rituximab

Intervention Type: BIOLOGICAL

Intravenous infusion 375 mg/m\^2.

N-803

Intervention Type: BIOLOGICAL

Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

Phase 2 Cohort 2: Anti-CD20 mAb-refractory N-803 - SQ 20 ug/kg

Group Type: EXPERIMENTAL

Rituximab

Intervention Type: BIOLOGICAL

Intravenous infusion 375 mg/m\^2.

N-803

Intervention Type: BIOLOGICAL

Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

Interventions

Rituximab

Intravenous infusion 375 mg/m\^2.

Intervention Type: BIOLOGICAL

N-803

Intravenous infusion for Phase 1 cohort 1, 2 and 3; subcutaneous injection for Phase 1 cohort 4, 5, 6 and 7. Phase 2 dosing was based off of the MTD determined in Phase 1.

Intervention Type: BIOLOGICAL

Other Intervention Names

Rituxin

Eligibility Criteria

Inclusion Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed diagnosis of iNHL (Follicular lymphoma grade 1, 2, 3a; marginal zone lymphoma; small lymphocytic lymphoma or lymphoplasmacytic lymphoma) after treatment with at least 1 or more prior rituximab-containing regimens.

• Anti-CD20 mAb-refractory disease is defined as progressive disease while on rituximab (or another treatment of an anti-CD20 monoclonal antibody) or progression within 6 months of rituximab-containing (or another treatment of an anti-CD20 antibody-containing) therapy.
• Anti-CD20 mAb-sensitive disease is defined by a response to a prior rituximab-containing (or another treatment of an anti-CD20 monoclonal antibody) regimen, and relapse more than 6 months from the last administration of rituximab-containing (or another treatment of an anti-CD20 antibody-containing) therapy.
• Measurable disease:

• At least one lymph node group ≥ 1.5 cm in longest transverse dimension. Patients with cutaneous only disease may be enrolled if they have a clearly measurable skin lesion.
• Relapsed or Refractory iNHL that has progressed during or following 1 or more prior systemic rituximab-containing (or another treatment of an anti-CD20 antibody-containing) regimens for lymphoma

PRIOR/CONCURRENT THERAPY:

• No anti-lymphoma treatments within 28 days before the start of study treatment.
• Must have recovered from side effects of prior treatments.

PATIENT CHARACTERISTICS:

Performance Status

• ECOG 0, 1, or 2

Renal Function • Glomerular Filtration Rate (GFR) > 40mL/min or Serum creatinine ≤ 1.5 X ULN

Bone Marrow Reserve

• Platelets ≥30,000/uL
• Hemoglobin ≥ 8g/dL
• Absolute Lymphocytes ≥800/uL
• ANC/AGC ≥750/uL

Hepatic Function

• Total bilirubin ≤ 2.0 X ULN (unless Gilbert's Syndrome or disease infiltration of liver is present)
• AST, ALT ≤ 3.0 X ULN, or ≤ 5.0 X ULN (if liver lymphoma is present)
• No positive Hep C serology or active Hep B infection

Cardiovascular

• No congestive heart failure < 6 months
• No unstable angina pectoris < 6 months
• No myocardial infarction < 6 months
• No history of ventricular arrhythmias or severe cardiac dysfunction
• No history of uncontrollable supraventricular arrhythmias
• No NYHA Class > II CHF
• No marked baseline prolongation of QT/QTc interval

Pulmonary

• Normal clinical assessment of pulmonary function

Other

• Negative serum pregnancy test if female and of childbearing potential
• Women who are not pregnant or nursing
• Subjects, both females and males, with reproductive potential must agree to use effective contraceptive measures for the duration of the study
• No known autoimmune disease other than corrected hypothyroidism
• No known prior organ allograft or allogeneic transplantation
• Not HIV positive
• No active CNS involvement with lymphoma
• No psychiatric illness/social situation that would limit compliance
• No other illness that in the opinion of the investigator would exclude the subject from participating in the study
• Must provide informed consent and HIPPA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations
• No active systemic infection requiring parenteral antibiotic therapy
• No disease requiring systemic immunosuppressive therapy (inhaled or topical steroids are allowed). Adrenal replacement steroid doses ≤ 10 mg daily prednisone equivalent are permitted in the absence of active autoimmune disease.
• No known histologic transformation from iNHL to DLBCL

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Altor BioScience

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of Minnesota Cancer Center

Minneapolis, Minnesota, United States

Washington University School of Medicine Oncology

St Louis, Missouri, United States

The Ohio State University

Columbus, Ohio, United States

Medical University of South Carolina

Charleston, South Carolina, United States

Countries

United States

References

Foltz JA, Hess BT, Bachanova V, Bartlett NL, Berrien-Elliott MM, McClain E, Becker-Hapak M, Foster M, Schappe T, Kahl B, Mehta-Shah N, Cashen AF, Marin ND, McDaniels K, Moreno C, Mosior M, Gao F, Griffith OL, Griffith M, Wagner JA, Epperla N, Rock AD, Lee J, Petti AA, Soon-Shiong P, Fehniger TA. Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 Jun 15;27(12):3339-3350. doi: 10.1158/1078-0432.CCR-20-4575. Epub 2021 Apr 8.

Reference Type: DERIVED

PMID: 33832946 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Related Links

https://pubmed.ncbi.nlm.nih.gov/33832946/

Related Info

Other Identifiers

CA-ALT-803-02-14

Identifier Type: -

Identifier Source: org_study_id